IGC-AD1 Is a Potential Treatment for Alzheimer Disease Agitation, According to Interim Phase 2 Data.

Published Date: 24 Mar 2024

Patients on IGC-AD1 saw a greater average decrease in agitation scores over the course of six weeks when compared to those on placebo; benefits were observed as early as week two.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot